Nicole Lambert compensation by year
MYRIAD GENETICS Summary Compensation Table · all 6 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|
| Salary | $319,072 | $369,169 | $386,859 | $475,250 | $498,933 | $448,745 |
| Bonus | $0 | $0 | $0 | — | — | $0 |
| Stock awards | $278,474 | $416,626 | $1,197,200 | $2,086,457 | $1,849,751 | $3,810,058 |
| Option awards | $0 | $0 | $0 | — | — | $0 |
| Non-equity incentive | $94,860 | $194,198 | $99,934 | $336,192 | $213,000 | $393,975 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $10,863 | $13,795 | $20,713 | $13,785 | $34,979 | $65,630 |
| Total | $703,269 | $993,788 | $1,704,706 | $2,911,684 | $2,596,663 | $4,718,409 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MYRIAD GENETICS INC DEF 14A filed April 17, 2024, accession 0000899923-24-000022, and prior-year filings. Open the filing on EDGAR.
How this page was built: the MYRIAD GENETICS INC filed document, accession 0000899923-24-000022. Every figure is read from that document and cited to the page and table it appears in. Filed April 17, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 33,664 | $644,329 | — |
| RSU | 21,646 | $414,304 | — |
| RSU | 16,832 | $322,164 | — |
| RSU | 16,467 | $315,178 | — |
| RSU | 14,778 | $282,851 | — |
| RSU | 11,052 | $211,535 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in MYRIAD GENETICS INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments MYRIAD GENETICS discloses, by trigger · FY2022| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $500,000 | $2,481,442 | $28,521 | $3,609,963 |
| Change in control and involuntary termination | $500,000 | $2,858,543 | $28,521 | $3,987,064 |
Per the Potential Payments Upon Termination or Change in Control table in MYRIAD GENETICS INC's FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.
MYRIAD GENETICS’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Paul Diaz | President and Chief Executive Officer | $12,108,359 |
| R. Bryan Riggsbee | Former Chief Financial Officer | $5,836,764 |
| Samraat Raha | Chief Operating Officer | $5,017,416 |
| Nicole Lambert · this page | Former Chief Operating Officer | $4,718,409 |
| Mark Verratti | Chief Commercial Officer | $2,875,089 |
| Dale Muzzey | Chief Scientific Officer | $2,231,550 |
The full MYRIAD GENETICS compensation record
free company briefThis page is one person within MYRIAD GENETICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the MYRIAD GENETICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MYRIAD GENETICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.